Source comparison
MOTS-c Mitochondrial Dysfunction Research: Comparison
MOTS-c Mitochondrial-derived peptide; retrograde signaling to nucleus Direct—binds folate enzymes to trigger AMPK cascade Increases PGC-1α expression; 28% mitochondrial content increase in aged tissue No published human RCTs as of 2026 Most direct mitochondria
This comparison does not assign a generated winner or score.
- MOTS-c
- Mitochondrial-derived peptide; retrograde signaling to nucleus
- Direct—binds folate enzymes to trigger AMPK cascade
- Increases PGC-1α expression; 28% mitochondrial content increase in aged tissue
- No published human RCTs as of 2026
- Most direct mitochondrial-to-nuclear signaling mechanism; limited human safety data
- Metformin
- Inhibits mitochondrial Complex I; reduces hepatic glucose output
- Indirect—AMPK activation secondary to ATP depletion
- Moderate—improves mitochondrial efficiency but doesn't increase biogenesis
- Extensive—decades of T2D use; TAME trial ongoing for aging
- Proven metabolic benefits; GI side effects in 25–30% of users
- Nicotinamide Riboside (NR)
- NAD+ precursor; supports mitochondrial electron transport
- Indirect—through NAD+-dependent pathways
- Increases NAD+ levels 40–90%; supports but doesn't directly trigger biogenesis
- Limited—small trials show NAD+ elevation but inconsistent metabolic outcomes
- Effective NAD+ booster; unclear if this translates to functional mitochondrial improvement
- Exercise (endurance)
- Mechanical stress; energy depletion signals
- Direct—sustained AMPK activation during activity
- Strong—consistent PGC-1α upregulation; gold-standard for mitochondrial adaptation
- Extensive observational and intervention data
- Most robust evidence; requires time investment and adherence
- Resveratrol
- Sirtuin activator (SIRT1); mimics caloric restriction
- Indirect—through SIRT1-AMPK crosstalk
- Weak to moderate in human studies; strong in rodent models
- Mixed—some trials show no metabolic benefit
- Bioavailability issues limit effectiveness; high doses required